Low-dose naltrexone (LDN): potential advantages and reasons to consider it

Low-dose naltrexone, or LDN, comes up often in conversations about chronic pain, fibromyalgia and inflammation. Here’s what it is, why people use it, and what the evidence does and does not show.

What is low-dose naltrexone?

Naltrexone was developed and approved at standard doses for opioid and alcohol dependence. At much smaller doses, typically about 0.5 to 4.5 mg taken once daily at night, it is used off-label for a range of chronic conditions. Because the dose is far below the standard prescription strength, it is usually obtained through a compounding pharmacy and must be prescribed after an individual evaluation.

Why it is thought to work

The leading proposal is that low doses briefly block opioid receptors, which prompts the body to produce more of its own endorphins. Lower-dose naltrexone is also thought to reduce inflammatory signaling in glial (immune) cells in the nervous system by modulating Toll-like receptor 4. These mechanisms are plausible and studied, but they are not yet fully proven in patients.

Potential advantages

  • Chronic pain. This is the area with the most controlled research. A 2026 narrative review found that the strongest controlled evidence is in chronic pain, though early positive findings have not yet been reproduced in larger, more recent trials.

  • Fibromyalgia. A 2025 systematic review and meta-analysis concluded that LDN is effective for fibromyalgia and reported no serious adverse effects in the treatment groups, while calling for more randomized trials.

  • A non-opioid option. LDN is described in the literature as a possible opioid-free approach to pain management, which may matter for patients who want to limit opioid exposure.

  • Generally well tolerated. At low doses, side effects are usually mild and short-lived. The most reported include vivid dreams, sleep changes, headache and nausea.

  • Affordable. LDN is inexpensive compared with many specialty treatments, which is one reason it is considered for long-term use.

  • Other conditions. Research is under way in autoimmune, neuroimmune, dermatologic and other areas. Most of this evidence is currently small, uncontrolled or anecdotal.

Why it is often considered

  • People with long-standing pain conditions who want options beyond opioids or heavy medication loads.

  • Individuals with inflammatory or immune-related symptoms who are working with a clinician on a broader plan.

  • Patients looking for a low-cost medication with a long track record of use at low doses.

Full-dose naltrexone: a different use

Full-dose naltrexone is an FDA-approved medication, usually 50 mg by mouth once daily, or a monthly injection in addiction care. It is used for alcohol dependence and for opioid dependence. At this dose it blocks opioid receptors for most of the day. That is what makes it useful in addiction treatment, and also why it cannot be combined with opioid pain medicines.

  • Alcohol dependence: 50 mg once daily for most patients.

  • Opioid dependence: start at 25 mg, then move to 50 mg if no withdrawal occurs.

  • Before starting, patients must be opioid-free for 7 to 10 days, confirmed by urine screen and a naloxone challenge when there is doubt.

  • Naltrexone is contraindicated with opioid analgesics, and tramadol counts as an opioid for this purpose.

Full-dose naltrexone is not advised for people who are neither opioid-dependent nor alcohol-dependent. This includes people seeking it for chronic pain, fibromyalgia or autoimmune conditions. Those uses rely on the low-dose effect, and a full dose would produce sustained opioid blockade without evidence of benefit for them. The one clinician-directed exception is traumatic brain injury, where higher doses of 50 mg or more may be used until a patient is stabilized, before moving to chronic low doses.

Titration: how LDN is built up

LDN is started low and increased slowly, usually over several weeks. There is no single official schedule. Common approaches from pharmacists and patient organizations include:

  • Starting dose: commonly 0.5 mg to 1.5 mg nightly.

  • Schedule A: 1 mg, increasing by 1 mg each week, reaching 4.5 mg by about week five.

  • Schedule B: 0.5 mg, increasing by 0.5 mg every two weeks until the maximum tolerated dose is reached.

  • Schedule C: 1.5 mg, increasing by 1.5 mg every two weeks to 4.5 mg, then two to three months at the target dose to judge benefit.

Flexibility in titration

  • Pace follows sensitivity. Sensitive patients may start at 0.1 mg and rise in 0.1 mg steps, while others can move faster if no effects appear.

  • Hold or step back. If sleep changes or vivid dreams are bothersome, stay at the current dose for an extra week, or drop back to about 3 mg, where side effects often ease.

  • Timing matters. Taking the dose at bedtime, about one to two hours before sleep, can limit sleep disruption.

  • The ceiling is individual. Most people settle between 3 and 4.5 mg. Some reach 4.5 to 6 mg, and a small number of specialist protocols use very low doses given several times a day for complex chronic pain.

  • Formulation affects precision. Compounded liquids can be measured in increments as small as 0.1 mg, while capsules are coarser.

  • Reassess over time. Benefit usually needs a trial of two to three months at a stable dose before judging the result.

The final plan is set by the prescriber, based on the patient’s condition, sensitivity and response.

Important limits of the evidence

A 2026 narrative review covered 105 studies, but only 15 were randomized controlled trials. Those trials spanned seven conditions, and most of the remaining evidence came from case reports, small case series and observational studies. Results for many uses therefore remain promising rather than settled. Clinicians should be transparent about this, and patients should expect a trial period with clear goals rather than a guaranteed result.

Who should not take LDN without medical guidance

  • Anyone taking opioid medications or using opioids, because naltrexone blocks opioid effects and can precipitate withdrawal.

  • Anyone with liver disease, kidney problems or a history of opioid use disorder.

  • Pregnant or breastfeeding individuals, and anyone planning a pregnancy.

  • Anyone taking other medications or supplements, which should be reviewed for interactions first.

A sensible path forward

LDN is a prescription option, not an over-the-counter supplement. A careful approach includes a full history and medication review, baseline labs where appropriate, a clear starting dose, defined goals for symptoms or function, and follow-up to assess benefit and side effects.

Ready to learn whether LDN fits your health goals? Call or text (602) 894-8398 to ask about a free 15-minute discovery call, or book online.

Sources

Educational information only. Not a substitute for evaluation by a licensed clinician.

Next
Next

5 things you can do today to lower inflammation and calm your stress hormones